 Ocular involvement can be quite symptomatic in patients with chronic graft-versus-host disease GVHD. The impact of ocular GVHD on quality of life QOL in patients with chronic GVHD has been studied in a prospective, multicenter, longitudinal, observational study and showed that ocular GVHD affects 57 of patients within 2 years of chronic GVHD diagnosis. Strong evidence suggested that ocular GVHD is associated with worse overall health-related QOL. Significant worsening of vision-related QOL in ocular GVHD has been reported. Ocular GVHD is devastating and there is no effective treatment available so far. The importance of this study is that for the first time in the nation, our institute will evaluate the safety and efficacy of topical autologous blood product PRP and PPP to treat ocular surface disease associated with ocular GVHD. 